September 28, 2022

China's large vaccine producer Sinopharm and US pharmaceutical giant Merck Sharp & Dohme (MSD) signed a cooperation framework agreement on Wednesday, under which Sinopharm would be a dealer and exclusive commission agent of MSD's antiviral COVID-19 medicine in China. 

The two sides will also negotiate the feasibility of a technical transfer under the framework so that the drug Molnupiravir could be produced and provided in the Chinese mainland market, according to a statement Sinopharm sent to the Global Times on Wednesday. 

Application materials for approval of the drug in the mainland have been submitted. Under the cooperation framework, Sinopharm would obtain dealership and exclusive import rights of Molnupiravir. Sinopharm would actively promote the localization of production and provision of the treatment after MSD transfers the techniques in order to help China to fight the pandemic, according to the statement. 

Read more:

https://www.globaltimes.cn/page/202209/1276352.shtml